You can buy or sell ADVM and other stocks, options, ETFs, and crypto commission-free!
Adverum Biotechnologies, Inc. Common Stock, also called Adverum Biotechnologies, is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. Read More It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
Menlo Park, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 ...
Seeking AlphaMar 12
Adverum Biotechnologies (ADVM) Investor Presentation - Slideshow
The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this event. 1 21 Click to enlarge Notes:...
Expected May 8, After Hours